Market Overview:
The global chemotherapy induced anemia market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, growing geriatric population, and rising demand for better treatment options. Based on type, the global chemotherapy induced anemia market is segmented into mild anemia, moderate anemia, severe anemia, and life-threatening anemia. Severe anaemia accounts for the largest share of the global chemotherapy induced anaemia market in 2018. This segment is expected to grow at a CAGR of 5% during the forecast period due to increasing incidence of cancer and growing demand for better treatment options. Moderate anaemia accounted for second largest share in 2018 and it is projected to grow at a CAGR of 6% during the forecast period owing to increase in awareness about early diagnosis and treatment options among patients with cancer across different geographies.
Product Definition:
Chemotherapy Induced Anemia is a decrease in the number of red blood cells (RBCs) and/or hemoglobin in the blood as a result of chemotherapy. Chemotherapy-induced anemia can cause fatigue, shortness of breath, and other problems.
Mild Anemia:
Mild anemia is the most common type of anemia. It is also known as pernicious or chronic anemia. According to the National Institutes of Health, about 2% to 5% of women and 1% to 3% of men have this condition at some time in their lives.
Moderate Anemia:
Moderate anemia is also known as chronic blood loss anemia. It is a condition wherein the total amount of hemoglobin in the blood is less than normal or expected value for a particular person. There are different types of causes for this condition which include infections, genetic disorders, and dietary habits among others.
Application Insights:
The market is segmented into hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers and cancer rehabilitation centers. Hospitals held the largest share of the application segment in 2017. Chemotherapy induced anemia is most commonly seen in patients undergoing chemotherapy or radiation therapy as a result of which they are admitted to hospital for treatment. This leads to an increase in demand for CIGA devices during this period which subsequently increases revenue generation capacity of healthcare providers and manufacturers operating within the industry.
Ambulatory surgical center (ASC) was estimated as the second-largest revenue generating segment owing to increasing awareness about availability of advanced therapies coupled with rising incidences of blood disorders among adults across developed nations such as U.S.
Regional Analysis:
North America dominated the global chemotherapy induced anemia market in 2017. This can be attributed to the local presence of major players, high adoption of novel treatment options, and availability of well-developed healthcare infrastructure. Moreover, increasing incidence rates of cancer is also one among the key factors responsible for regional growth. According to statistics published by American Cancer Society in 2018, 1 out of 6 Americans will be diagnosed with cancer during their lifetime and it is estimated that 1 person dies due to it every 42 minutes.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the chemotherapy induced anemia market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise in the coming years. This will lead to an increase in demand for chemotherapy induced anemia drugs and therapies, thereby driving market growth.
- Rising prevalence of chronic diseases: The rising prevalence of chronic diseases such as diabetes and heart disease is also contributing to market growth, as these conditions can increase the risk for developing chemotherapy induced anemia.
- Growing awareness about CEA: There has been a growing awareness among patients and healthcare professionals about CEA over recent years, which is helping to drive demand for related drugs and therapies. This increased awareness is likely to continue in future, propelling market growth further..
Scope Of The Report
Report Attributes
Report Details
Report Title
Chemotherapy Induced Anemia Market Research Report
By Type
Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia
By Application
Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers
By Companies
Dr. Reddy’s Laboratories, Pfizer, Panacea Biotec, SBio, SBI Pharmaceuticals, Tolero Pharmaceuticals, Vifor Pharma, Therapure Biopharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Chemotherapy Induced Anemia Market Report Segments:
The global Chemotherapy Induced Anemia market is segmented on the basis of:
Types
Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy’s Laboratories
- Pfizer
- Panacea Biotec
- SBio
- SBI Pharmaceuticals
- Tolero Pharmaceuticals
- Vifor Pharma
- Therapure Biopharma
Highlights of The Chemotherapy Induced Anemia Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Mild Anemia
- Moderate Anemia
- Severe Anemia
- Life-Threatening Anemia
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Multispecialty Clinics
- Cancer Research Centers
- Cancer Rehabilitation Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chemotherapy Induced Anemia Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chemotherapy induced anemia is a condition that results from the chemotherapy treatment. The chemotherapy damages the bone marrow and makes it difficult for the body to produce red blood cells.
Some of the key players operating in the chemotherapy induced anemia market are Dr. Reddy’s Laboratories, Pfizer, Panacea Biotec, SBio, SBI Pharmaceuticals, Tolero Pharmaceuticals, Vifor Pharma, Therapure Biopharma.
The chemotherapy induced anemia market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemotherapy Induced Anemia Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemotherapy Induced Anemia Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemotherapy Induced Anemia Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemotherapy Induced Anemia Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemotherapy Induced Anemia Market Size & Forecast, 2020-2028
4.5.1 Chemotherapy Induced Anemia Market Size and Y-o-Y Growth
4.5.2 Chemotherapy Induced Anemia Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Mild Anemia
5.2.2 Moderate Anemia
5.2.3 Severe Anemia
5.2.4 Life-Threatening Anemia
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Multispecialty Clinics
6.2.4 Cancer Research Centers
6.2.5 Cancer Rehabilitation Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemotherapy Induced Anemia Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemotherapy Induced Anemia Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Mild Anemia
9.6.2 Moderate Anemia
9.6.3 Severe Anemia
9.6.4 Life-Threatening Anemia
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Multispecialty Clinics
9.10.4 Cancer Research Centers
9.10.5 Cancer Rehabilitation Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Mild Anemia
10.6.2 Moderate Anemia
10.6.3 Severe Anemia
10.6.4 Life-Threatening Anemia
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Multispecialty Clinics
10.10.4 Cancer Research Centers
10.10.5 Cancer Rehabilitation Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Mild Anemia
11.6.2 Moderate Anemia
11.6.3 Severe Anemia
11.6.4 Life-Threatening Anemia
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Multispecialty Clinics
11.10.4 Cancer Research Centers
11.10.5 Cancer Rehabilitation Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Mild Anemia
12.6.2 Moderate Anemia
12.6.3 Severe Anemia
12.6.4 Life-Threatening Anemia
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Multispecialty Clinics
12.10.4 Cancer Research Centers
12.10.5 Cancer Rehabilitation Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Mild Anemia
13.6.2 Moderate Anemia
13.6.3 Severe Anemia
13.6.4 Life-Threatening Anemia
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Multispecialty Clinics
13.10.4 Cancer Research Centers
13.10.5 Cancer Rehabilitation Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemotherapy Induced Anemia Market: Competitive Dashboard
14.2 Global Chemotherapy Induced Anemia Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy’s Laboratories
14.3.2 Pfizer
14.3.3 Panacea Biotec
14.3.4 SBio
14.3.5 SBI Pharmaceuticals
14.3.6 Tolero Pharmaceuticals
14.3.7 Vifor Pharma
14.3.8 Therapure Biopharma
